Accordingly, studies have shown that patients with CRC have significantly higher serum CCL20 and interkeukin-17 A (IL17A) levels than healthy individuals, and that receiver operating characteristic curve analysis combining CCL20 and IL17A is effective in distinguishing patients with CRC from healthy individuals [42]. This evidence concerns the gene CCL20 and colorectal carcinoma.